|
Jan 5
|
Orion and MSD Announce Initiation of Two Phase 3 Trials Evaluating ODM-208/MK5684 in Certain Patients with Metastatic Castration-Resistant Prostate Cancer
|
|
Dec 4
|
87 000 Orion Corporation A shares converted into B shares
|
|
Jul 19
|
Orion Corporation: Managers’ transactions – Veli-Matti Mattila
|
|
Jul 17
|
Orion Group Half-Year Financial Report 1–6/2023
|
|
Jul 17
|
Orion Corporation's financial reporting and Annual General Meeting in 2024
|